Graft Protection is Just the Start: Provide long-term benefits with Certican®
Looking ahead post kidney
transplant management
Effective graft protection post kidney transplant with Certican® + CNI
High Graft Function
after 24 months1
32.9% (95%CI:-2.2%, 13.0%)
Low rates of:
• Treated biopsy-proven
acute rejection
• Graft loss
• Death
Tolerable safety profile
AEs were generally mild to moderate in severity1
Provide long-term benefits beyond graft protection
Almost no changes in eGFR
after 12 months2
Negative change in eGFR
from month 1 to month 12
Lower CMV and BKV infection
after 24 months3
-CMV (Certican+rCNI, 2.8% vs.
MPA+sCNI, 13.5%)
-BK virus (5.8% vs 10.3%)
Lower incidence of MACE
after 24 months1
2.9% Certican+rCNI vs.
4.0% in MPA+sCNI
Reduced risk of any cancer
after median follow-up of 7.3 years4
57% reduction for any cancers;
95% CI 0.18, 1.02
Certican® is an mTOR inhibitor that acts synergistically with CNIs to suppress immune response5
Abbreviations:
CNI, Calcineurin inhibitors; CV, cardiovascular; mTOR, mammalian target of rapamycin; CMV, cytomegalovirus
References:
1. Cibrik, Diane, et al. Transplantation. 2013;95(7):933–942; 2. Shihab FS, et al. Clin Transplant .2013: 27: 217–226; 3. Berger SP, et al. Am J Transplant. 2019; 00: 1–17; 4. Lim WH, et al. Kidney Int. 2017;91(4):954-963; 5. Su L, et al. Int Urol Nephrol. 2014;46(10):2035-2044; 6. Mao B, etal. Molecules. 2022;27(16):5295
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
FOR HEALTHCARE PROFESSIONALS ONLY
APPROVAL CODE
